Home Tags WuXi Biologics

Tag: WuXi Biologics

Signing Ceremony between Ambrx an NovoCodex. Courtesy 2019 NovoCodex.

Ambrx and Novocodex to Jointly Develop and Commercialize 2nd Antibody-drug Conjugate

Novocodex Biopharmaceuticals, a subsidiary of Zhejiang Medicine, and  Ambrx, a privately-held clinical stage biopharmaceutical company, have confirmed that the companies will jointly develop and...
On October 16, 2019 Novocodex Biopharmaceuticals, a subsidiary of Zhejiang Medicine, and WuXi Biologics signed a strategic partnership for Phase III clinical trial production of ARX788 as well ongoing large-scale commercial production of the innovative antibody-drug conjugate.

WuXi Biologics Opens New Facility to Supports Novocodex ADC Manufacturing

Earlier this month China-based Contract Research Organization (CRO) WuXi Biologics started commercial production at the company's new Current Good Manufacturing Practice (cGMP)-approved DP3 bulk...
WuXi Biologics Conjugation Solution Center

WuXi Biologics Expands Integrated Biologics Conjugation Solution Center

WuXi Biologics ("WuXi Bio") (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing, announced that...

WuXi Biologics and NBE-Therapeutics Collaborate in Development and Manufacturing Partnership

WuXi Biologics, an open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing, and Swiss biotech NBE-Therapeutics, developing best-in-class, next-generation...

WuXi Biologics Starts Construction of a State-of-the-Art R&D and Manufacturing Center...

WuXi Biologics, a Hong Kong-listed, open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing, has started the construction of...